🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Cuauhtémoc
Clinical trial register · Mexico

Clinical Trials in Cuauhtémoc, 2026

Every study on the ClinicalTrials.gov registry that lists a site in Mexico and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage — all 1579 matching records held by the registry are in this view. Synced 26 Sep 2026, 19:45 UTC
1579
Studies in scope
all four open statuses
711
Recruiting now
open to new participants
247
Lead sponsors
across recruiting studies
Top sites
Mexico City 586 Monterrey 370 Guadalajara 342 Chihuahua City 175 Mérida 135
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
AstraZeneca6 Amgen3 Novo Nordisk A/S3 Pfizer3 Bristol-Myers Squibb2
Site location
Mexico City586 Monterrey370 Guadalajara342 Chihuahua City175 Mérida135
All 197 locations
Target enrolment
to

Trials with a site in Cuauhtémoc

33 of 1579 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Sites in Mexico
Start
Recruiting
A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Placebo in Children and Adolescents With Type 2 Diabetes
NCT07282613Diabetes Mellitus, Type 2
DrugCagriSema
Novo Nordisk A/S
Phase 3
80
Coyoacán, Monterrey, San Nicolás de los Garza, Cuauhtémoc, Puebla City
2026-08-04
Recruiting
A Research Study to Look at How Well NNC0487-0111 Works Compared to Placebo in People With Heart Failure and Obesity
NCT07567001Obesity, Heart Failure
DrugNNC0487-0111
Novo Nordisk A/S
Phase 3
5,610
Col. Zona Comercial Plaza Del Sol, Torreón, León, Actopan, Guadalajara, Col Roma Norte, Cuauhtémoc, Tlalpan
2026-05-11
Recruiting
A Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes)
NCT07165028Metabolic Dysfunction-Associated Steatotic Liver Disease
DrugsRetatrutide·Tirzepatide
Eli Lilly and Company
Phase 3
4,500
Chihuahua City, Cuauhtémoc, Cuernavaca, Guadalajara, Metepec, Mexico City, Mérida, Monterrey
2025-10-15
Recruiting
Evaluating the Impact of Maridebart Cafraglutide on Cardiovascular Outcomes in Participants With Atherosclerotic Cardiovascular Disease and Overweight or Obesity
NCT07037433Atherosclerotic Cardiovascular Disease, Overweight, Obesity
DrugMaridebart cafraglutide
Amgen
Phase 3
12,800
Guadalajara, Mexico City, Cuernavaca, Monterrey, Culiacán, Tampico, Mérida, Cuauhtémoc
2025-07-25
Recruiting
A Phase III Study of AZD0780 on Major Adverse CV Events in Patients With a History of ASCVD Events or at High Risk for a First Event
NCT07000357Cardiovascular Disease
DrugAZD0780
AstraZeneca
Phase 3
15,100
Acapulco, Aguascalientes, Chihuahua City, Cuauhtémoc, Cuernavaca, Culiacán, Guadalajara, Mexico City
2025-06-04
Recruiting
A Study to Evaluate the Efficacy and Safety of Sacituzumab Tirumotecan (MK-2870) Maintenance Treatment Versus Standard of Care in Participants With Platinum-sensitive Recurrent Ovarian Cancer (MK-2870-022/TroFuse-022/ENGOT-ov84/GOG-3103)
NCT06824467Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer
DrugsSteroid mouthwash (dexamethasone·Mvasi·Acetaminophen·Avastin
Merck Sharp & Dohme LLC
Phase 3
770
Guadalajara, Mexico City, Monterrey, Aguascalientes, Cuauhtémoc, Oaxaca City
2025-04-09
Recruiting
A Study to Investigate the Efficacy and Safety of Tezepelumab in Adult Participants With Moderate to Very Severe COPD (D5241C00006)
NCT06883305Chronic Obstructive Pulmonary Disease (COPD)
DrugTezepelumab
AstraZeneca
Phase 3
990
Benito Juárez, Chihuahua City, Cuauhtémoc, Cuernavaca, Guadalajara, Mérida, Monterrey, Morelia
2025-03-18
Recruiting
Phase III Study Investigating Heart Failure and Cardiovascular Death With Baxdrostat in Combination With Dapagliflozin
NCT06677060Heart Failure
AstraZeneca
Phase 3
11,300
Acapulco, Aguascalientes, Cuauhtémoc, Cuernavaca, Culiacán, Durango, Guadalajara, Mexico City
2025-03-14
Recruiting
A Phase III Renal Outcomes and Cardiovascular Mortality Study to Investigate the Efficacy and Safety of Baxdrostat in Combination With Dapagliflozin in Participants With Chronic Kidney Disease and High Blood Pressure
NCT06742723Chronic Kidney Disease and Hypertension
DrugBaxdrostat/dapagliflozin
AstraZeneca
Phase 3
5,000
Chihuahua City, Cuauhtémoc, D.F, Durango, Guadalajara, Mazatlán, Mérida, San Luis Potosí City
2025-03-03
Active, closed
A Phase 3 Study to Assess Efficacy Safety and Tolerability of Remibrutinib in Adult and Adolescent Patients With Moderate to Severe Hidradenitis Suppurativa (RECHARGE 1)
NCT06799000Hidradenitis Suppurativa
DrugsRemibrutinib A·Remibrutinib B
Novartis Pharmaceuticals
Phase 3
588
Guadalajara, Cuauhtémoc, Chihuahua City
2025-01-31
Recruiting
A Study to Understand How the Study Medicine Dazukibart Works in People With Idiopathic Inflammatory Myopathies
NCT06698796Dermatomyositis, Polymyositis
Pfizer
Phase 3
211
Cuauhtémoc
2025-01-22
Active, closed
A Study of Enicepatide (CT-388) in Participants Who Are Overweight or Obese With Type 2 Diabetes Mellitus
NCT06628362Overweight or Obese, Type 2 Diabetes Mellitus (T2DM)
Carmot Therapeutics, Inc.
Phase 2
447
Cuauhtémoc, Cuernavaca, Culiacán, Mexicali, Mexico City, Mérida, San Pedro Garza García, Veracruz
2024-11-21
Active, closed
Open-label Study to Assess Reduction of Background Asthma Medication While Sustaining Asthma Control and Clinical Remission With Tezepelumab in Patients 12-80yrs With Severe Asthma.
NCT06473779Severe Asthma
AstraZeneca
Phase 3
326
Chihuahua City, Cuauhtémoc, Monterrey
2024-09-30
Active, closed
Pharmacokinetic Similarity Between ABP 234 and Keytruda® (Pembrolizumab)
NCT06430866Early-stage Non-squamous Non-small Cell Lung Cancer (NSCLC)
DrugsABP 234·Pembrolizumab
Amgen
Phase 3
163
León, Zapopan, Cuauhtémoc, Monterrey, Puebla City
2024-09-12
Recruiting
A Study Evaluating Efruxifermin in Subjects With Compensated Cirrhosis Due to NASH/MASH
NCT06528314NASH - Nonalcoholic Steatohepatitis, MASH - Metabolic Dysfunction-Associated Steatohepatitis
DrugEfruxifermin
Akero Therapeutics, Inc
Phase 3
2,150
Acapulco de Juárez, Guadalajara, Cuauhtémoc, Mexico City, Mérida, Benito Juárez
2024-09-04
Active, closed
A Phase 3 Study of Barzolvolimab in Participants With Chronic Spontaneous Urticaria (CSU)
NCT06455202Chronic Spontaneous Urticaria
DrugBarzolvolimab
Celldex Therapeutics
Phase 3
976
Chihuahua City, Cuauhtémoc, Guadalajara, Mérida, Monterrey, Morelia, San Juan del Río, Veracruz
2024-07-19
Active, closed
ARTEMIS - A Research Study to Look at How Ziltivekimab Works Compared to Placebo in People With a Heart Attack
NCT06118281Cardiovascular Risk, Acute Myocardial Infarction (AMI)
DrugZiltivekimab
Novo Nordisk A/S
Phase 3
10,000
Aguascalientes, Torreón, Guadalajara, México, Tlalpan, Cuauhtémoc, Monterrey, Culiacán
2024-06-25
Active, closed
A Study Describing the Efficacy and Safety of Belimumab Administered in Adult Participants With Early Systemic Lupus Erythematosus (SLE)
NCT06411249Systemic Lupus Erythematosus
DrugBelimumab
GlaxoSmithKline
Phase 4
303
Cuauhtémoc, DF, Guadalajara Jalisco, León, Mexico City, Mérida, Monterrey Nuevo LeOn, San Luis Potosí City
2024-06-06
Recruiting
Study to Evaluate the Effect of Balcinrenone/Dapagliflozin in Patients With Heart Failure and Impaired Kidney Function
NCT06307652Heart Failure and Impaired Kidney Function
AstraZeneca
Phase 3
3,850
Aguascalientes, Chihuahua City, Cuauhtémoc, Culiacán, Guadalajara, Mazatlán, Metepec, Mexico City
2024-04-12
Active, closed
Study Evaluating Tarlatamab After Chemoradiotherapy in Limited-Stage Small-Cell Lung Cancer (LS-SCLC)
NCT06117774Limited Stage Small Cell Lung Cancer, Small Cell Lung Cancer
DrugTarlatamab
Amgen
Phase 3
404
Cuauhtémoc, Mexico City, Puebla City, Toluca
2024-02-20
Recruiting
A Study to Determine the Efficacy and Safety of Finerenone on Morbidity and Mortality Among Hospitalized Heart Failure Patients
NCT06008197Heart Failure, Acute Heart Failure
DrugFinerenone
Colorado Prevention Center
Phase 3
5,200
Aguascalientes, Culiacán, Guadalajara, Cuauhtémoc, Mexico City, Morelia, Monterrey, San Nicolás
2024-01-17
Recruiting
A Study Evaluating Efruxifermin in Subjects With Non-Cirrhotic Nonalcoholic Steatohepatitis (NASH)/Metabolic Dysfunction-Associated Steatohepatitis (MASH) and Fibrosis
NCT06215716NASH With Fibrosis, MASH With Fibrosis
DrugEfruxifermin
Akero Therapeutics, Inc
Phase 3
1,650
Cuauhtémoc
2023-12-01
Active, closed
Phase 3b Study to Assess the Efficacy, Safety, and Tolerability of Remibrutinib in Comparison to Placebo, With Omalizumab as Active Control, in Adult CSU Patients, Followed by an Open-label 52-week Optional Extension.
NCT06042478Chronic Spontaneous Urticaria
DrugsOmalizumab·Remibrutinib
Novartis Pharmaceuticals
Phase 3
470
Guadalajara, Cuauhtémoc, Villahermosa, Mérida
2023-11-15
Active, closed
Phase 2 Placebo-Controlled Study to Assess the Safety and Efficacy of ESK-001 in Active Systemic Lupus Erythematosus
NCT05966480SLE
DrugEnvudeucitinib
Alumis Inc
Phase 2
408
Naucalpan, Chihuahua City, Cuauhtémoc, Guadalajara, Madero, Mexico City, Mérida, Oaxaca City
2023-06-26
Recruiting
A Study to Understand How the Study Medicine (PF-06823859) Works in People With Active Idiopathic Inflammatory Myopathies [Dermatomyositis (DM) and Polymyositis (PM)]
NCT05895786Myositis
Pfizer
Phase 3
318
Guadajalara, Guadalajara, Cuauhtémoc, Mexico City, Cuernavaca
2023-05-20
Active, closed
A Study to Learn About a New Medicine Called Vepdegestrant (ARV-471, PF-07850327) in People Who Have Advanced Metastatic Breast Cancer
NCT05654623Advanced Breast Cancer
DrugsVepdegestrant·Fulvestrant
Pfizer
Phase 3
624
Guadajalara, Cuauhtémoc, Oaxaca City
2023-03-03
Active, closed
Datopotamab Deruxtecan (Dato-DXd) and Pembrolizumab With or Without Platinum Chemotherapy in 1L Non-Small Cell Lung Cancer (TROPION-Lung07)
NCT05555732Metastatic Non Small Cell Lung Cancer
DrugsDatopotamab Deruxtecan·Pemetrexed·Cisplatin·Carboplatin
Daiichi Sankyo
Phase 3
1,170
Cuauhtémoc, Guadalajara, Mexico City, Oaxaca City
2023-01-11
Active, closed
A Study of Tirzepatide (LY3298176) on the Reduction on Morbidity and Mortality in Adults With Obesity
NCT05556512Obesity, Overweight
DrugTirzepatide
Eli Lilly and Company
Phase 3
15,374
Aguascalientes, Chihuahua City, Ciudad Madero, Cuauhtémoc, Cuernavaca, Culiacán, Durango, Guadalajara
2022-10-11
Active, closed
Study of Dato-DXd Plus Pembrolizumab vs Pembrolizumab Alone in the First-line Treatment of Subjects With Advanced or Metastatic NSCLC Without Actionable Genomic Alterations
NCT05215340Metastatic Non Small Cell Lung Cancer
DrugsDatopotamab Deruxtecan·Pembrolizumab
Daiichi Sankyo
Phase 3
740
Cuauhtémoc, Guadalajara, Monterrey, Oaxaca City, San Luis Potosí City
2022-03-04
Active, closed
A Phase 3 Study Evaluating Efficacy and Safety of Lanifibranor Followed by an Active Treatment Extension in Adult Patients With (NASH) and Fibrosis Stages F2 and F3 ( NATiV3 )
NCT04849728NASH - Nonalcoholic Steatohepatitis
Inventiva Pharma
Phase 3
1,000
Guadalajara, Cuauhtémoc, Mexico City, Cuernavaca, Monterrey, Mérida, Metepec, Oaxaca City
2021-08-19
Recruiting
Pan Tumor Rollover Study
NCT03899155Cancer
DrugsRucaparib·Sunitinib·Relatlimab·Trametinib
Bristol-Myers Squibb
Phase 2
1,500
León, Zapopan, Cuauhtémoc, Tlalpan, Morelia, Monterrey, Oaxaca City, Querétaro City
2019-08-09
Active, closed
A Study of Nivolumab in Participants With Hepatocellular Carcinoma Who Are at High Risk of Recurrence After Curative Hepatic Resection or Ablation
NCT03383458Hepatocellular Carcinoma, Liver Cancer
DrugsOpdivo·Nivolumab
Bristol-Myers Squibb
Phase 3
545
Cuauhtémoc, Monterrey, San Luis Potosí City
2018-04-18
Active, closed
A Study Comparing Upadacitinib (ABT-494) to Placebo and to Adalimumab in Adults With Rheumatoid Arthritis Who Are on a Stable Dose of Methotrexate and Who Have an Inadequate Response to Methotrexate
NCT02629159Rheumatoid Arthritis
DrugsHumira·Adalimumab·Upadacitinib
AbbVie
Phase 3
1,629
Cuauhtémoc, Monterrey, Chihuahua City, Mexico City, Mérida
2015-12-01
Rows per page Showing 1–33 of 33
1
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a Mexican investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 26 September 2026. https://priyalifescience.com/clinical-trials-mexico/city/cuauht-moc

Query this register directly
GET /api/trials?country=in&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in Mexico and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 1,579 studies in total at the last sync on 26 Sep 2026, 19:45 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 33 of those studies with a site in Cuauhtémoc.

How many clinical trials are recruiting in Cuauhtémoc?

16 of the 33 studies on this page are recruiting new participants as of the 26 Sep 2026, 19:45 UTC sync. A further 0 have not yet opened recruitment, 17 are active but closed to new participants, and 0 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Cuauhtémoc), 33 studies
PhaseStudiesRecruitingShare
Phase 3291587.9%
Phase 2319.1%
Phase 4103%

Most active sponsors

Lead sponsors with the most studies (Cuauhtémoc)
Lead sponsorStudiesRecruiting
AstraZeneca65
Amgen31
Novo Nordisk A/S32
Pfizer32
Akero Therapeutics, Inc22
Bristol-Myers Squibb21
Daiichi Sankyo20
Eli Lilly and Company21
Novartis Pharmaceuticals20
AbbVie10
Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and China registers.